NCT05418348View on ClinicalTrials.gov

Relative Bioavailability of Intravenous GTX-104 Compared to Oral Nimodipine Capsules in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

August 26, 2021

Primary Completion Date

February 17, 2022

Study Completion Date

February 24, 2022

Conditions
Aneurysmal Subarachnoid Hemorrhage
Interventions
DRUG

GTX-104

new formulation of nimodipine injection for IV infusion

DRUG

Nimodipine Capsules

Nimodipine capsules (reference formulation)

Trial Locations (1)

Unknown

Clinical Research Unit, Montreal

Sponsors
All Listed Sponsors
lead

Grace Therapeutics Inc.

INDUSTRY

NCT05418348 - Relative Bioavailability of Intravenous GTX-104 Compared to Oral Nimodipine Capsules in Healthy Subjects | Biotech Hunter | Biotech Hunter